tirzepatide cardiovascular risk event assessment: a pre-specified meta-analysis Cardiovascular outcomes of semaglutide and

doi: 10.3390/nu12103050

This product has not been evaluated by regulatory authorities for the diagnosis, treatment, cure, or prevention of any disease.Always consult a qualified healthcare provider before beginning any new health protocol, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medication

Obesity can begin very early, with 12% of toddlers and primary school-aged children affected

Clinical Update 10/09/2025 Supplements and GLP-1 Meds Weve added information about the supplements berberine and Akkermansia, as well as the sweetener allulose, to our article about supplements and GLP-1 medications